The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Will Be The Estimated Market Valuation Of The Lateral Flow Immunoassay (LFIA) Based Rapid Test Market By The End Of 2030?
The market size for lateral flow immunoassay (lfia) based rapid tests has experienced consistent expansion in recent years. It is anticipated to grow from $7.17 billion in 2025 to $7.31 billion in 2026, reflecting a compound annual growth rate (CAGR) of 2.0%. The historical growth of this market can be linked to the increased scope of rapid infectious disease screening, the rising usage of pregnancy and fertility tests, the development of point-of-care diagnostics, the availability of cost-effective rapid tests, and an increase in public health screening efforts.
The lateral flow immunoassay (lfia) based rapid test market size is projected to experience consistent expansion over the upcoming years. By 2030, its value is anticipated to reach $8.67 billion, exhibiting a compound annual growth rate (CAGR) of 4.3%. This projected expansion is primarily driven by factors such as increased investments in decentralized diagnostics, the broadening scope of self-testing applications, a rising need for swift cardiac and toxicology tests, greater integration with digital health platforms, and an intensified focus on early disease detection. Key trends during this period encompass a surge in demand for rapid immunoassay-based testing, an increase in the uptake of home-use lfia kits, the growing utilization of multiplex detection assays, an expansion in infectious disease testing applications, and an elevated emphasis on user-friendly test designs.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3293&type=smp
What Drivers Are Shaping The Future Growth Of The Lateral Flow Immunoassay (LFIA) Based Rapid Test Market?
The expansion of the lateral flow immunoassay (LFIA) based rapid test market is anticipated to be spurred by the rising occurrence of chronic illnesses in the future. These chronic conditions, alternatively identified as non-communicable diseases (NCDs), represent enduring health issues that typically last for an individual’s entire life or a prolonged duration. LFIA-based rapid tests provide advantages such as prompt diagnosis, on-site testing, quick outcomes, continuous oversight, and contribute to lowering medical expenses associated with managing chronic diseases. Their value in managing chronic conditions stems from their ability to deliver quick and accessible results, empowering both patients and medical practitioners to swiftly decide on treatment plans and lifestyle adjustments. To illustrate, as reported by the National Health Service, a UK government department, in June 2024, there were 3,615,330 individuals listed with a general practitioner (GP) diagnosed with non-diabetic hyperglycemia or pre-diabetes (a state characterized by elevated blood sugar, though not sufficiently high for a diabetes diagnosis) in 2023. This represented an 18% rise from the 3,065,825 cases recorded in 2022. Consequently, the expanding occurrence of chronic illnesses is a key factor propelling the development of the lateral flow immunoassay (LFIA) based rapid test market.
Which Segment Classifications Shape The Lateral Flow Immunoassay (LFIA) Based Rapid Test Market?
The lateral flow immunoassay (lfia) based rapid test market covered in this report is segmented –
1) By Technique: Competitive Assay, Sandwich Assay, Multiplex Detection Assay
2) By Application: Infectious Disease, Pregnancy And Fertility, Toxicology, Cardiac Marker And Cholesterol Testing, Other Applications
3) By End-Users: Hospitals And Clinics, Diagnostic Laboratories, Home Care, Other End Users
Subsegments:
1) By Competitive Assay: Direct Competitive Assays, Indirect Competitive Assays
2) By Sandwich Assay: Single-step Sandwich Assays, Two-step Sandwich Assays
3) By Multiplex Detection Assay: Multi-analyte Assays, Simultaneous Detection Of Various Targets
How Are Trends Impacting The Lateral Flow Immunoassay (LFIA) Based Rapid Test Market?
Major companies active in the lateral flow immunoassay (LFIA)-based rapid test market are directing their efforts towards technologies like Integrated Health Solutions. This strategy is intended to improve diagnostic efficiency, simplify workflows, and ensure thorough patient care through enhanced data sharing and collaboration among healthcare platforms. Integrated Health Solutions encompass comprehensive healthcare systems that connect various services, technologies, and data to better patient care and streamline operations. For instance, in June 2024, F. Hoffmann-La Roche AG, a pharmaceutical company located in Switzerland, launched the analytical units for its Cobas Pro integrated solutions. The Cobas Pro system can handle up to 1,000 samples per hour with its sample supply unit and provides high-speed analytical units capable of performing up to 900 tests per hour for the ISE (ion-selective electrode) and 1,000 tests per hour for the Cobas C 503 unit, which focuses on clinical chemistry.
Which Companies Are Expanding Their Footprint In The Lateral Flow Immunoassay (LFIA) Based Rapid Test Market?
Major companies operating in the lateral flow immunoassay (lfia) based rapid test market are Abbott Laboratories, F. Hoffmann-La Roche, Quidel Corporation, Becton Dickinson and Company, Danaher Corporation, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., PerkinElmer Inc., Hologic Inc., LTEK Co. Ltd., JOYSBIO Biotechnology, Jiangsu Medomics Medical Technologies, Diagnocure, Ubio Biotechnology Systems, Elabscience® Immunoassay Kits, FyoniBio / Glycotope GmbH, Atomo Diagnostics Limited, INDICAL Bioscience, Lionex Gmbh, BIOMED Labordiagnostik GmbH, EKF Diagnostics, Launch Diagnostics, Diagnostic Instruments Ltd, Qiagen N.V., Merck KGaA, 3a Diagnostics, Roche Holding AG, Biomaxima, SensDx, Vitrosens Biotechnology, Bioeasy Biotechnology, Fujirebio, Immunodiagnostic Systems Holdings PLC, Mesa Biotech Inc, CTK Biotech
Read the full lateral flow immunoassay (lfia) based rapid test market report here:
Which Geographic Regions Are Influencing Demand In The Lateral Flow Immunoassay (LFIA) Based Rapid Test Market?
North America was the largest region in the lateral flow immunoassay (LFIA) based rapid test market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lateral flow immunoassay (lfia) based rapid test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3293&type=smp
Browse Through More Reports Similar to the Global Lateral Flow Immunoassay (LFIA) Based Rapid Test Market 2026, By The Business Research Company
Lateral Flow Assays Market Report 2026
https://www.thebusinessresearchcompany.com/report/lateral-flow-assays-global-market-report
Immunoassay Market Report 2026
https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report
Immunodiagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/immunodiagnostics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model